160mg Siogra Gold Sildenafil And Dapoxetine Tablets (100 mg Sildenafil / 60 mg Dapoxetine) - 4 Tablets Strip

The most frequently applied instrument in studies of PE is the Premature Ejaculation Profile, which is a validated tool designed to investigate various domains in PE and assess treatment efficacy.

Who is this product best suited for?

Clinical Decision & Treatment Plan

Perceived improvement in control over ejaculation

It comprises four self-reported items, each scored on a five-point scale, ie, perceived control over ejaculation, satisfaction with sexual intercourse, personal distress related to ejaculation, and interpersonal difficulty related to ejaculation.50 In addition, the Clinical Global Impression (CGI) of change is a validated instrument often used to give a measurement of overall perceived change in PE following treatment. The CGI (also called the patient-reported global impression of change in some studies) comprises just one item, ie, “Compared to the start of the study, how would you describe your premature ejaculation now?” Patients rate their response on a seven-point scale (−3 to +3) as: much worse, worse, slightly worse, no change, slightly better, better, or much better.51 Studies reporting patient responses to items on the Premature Ejaculation Profile and the CGI of change are listed in Table 2, with quality of evidence indications. Each of the patient-reported outcomes is assessed individually below. Changes from baseline in perceived control over ejaculation are reported for eight studies (Table 3).

All three integrated analyses found significant improvements in control over ejaculation at study endpoint.

• Future treatments may offer alternatives to Viagra with Dapoxetine.
• Research continues on more effective and safer combination drugs.
• Gene therapy and topical creams are under development for ED.
• Behavioral therapy remains a non-drug option for PE management.
• Stay informed about medical advances through reputable sources.
• Discuss new options with your doctor as they become available.
• Current medication remains reliable for many men worldwide.
• Maintain overall health to enhance any future treatment success.
• Always prioritize safety and professional guidance over convenience.

In McMahon et al, in which the results from five RCTs were integrated, the proportion of patients who reported at least “good” control after 12 weeks of dapoxetine therapy increased from a baseline of 0.6% to 26.2% with dapoxetine 30 mg, and from 0.5% to 30.2% with dapoxetine 60 mg, compared with 0.3% to 11.2% with placebo (P < viagra online generic 0.001 for both dapoxetine doses vs placebo).45 Note: Only data for patients without erectile dysfunction are shown for consistency with other studies. Abbreviations: CGI, Clinical Global Impression; NR, not reported; RCT, randomized, placebo-controlled trial; PBO, placebo; DPX, dapoxetine. The integrated analysis by Porst et al of two studies showed no differences in control over ejaculation between those with lifelong or acquired PE (and no erectile dysfunction), suggesting that the etiology of the two forms may be similar, given that dapoxetine treatment was equally effective.47 The proportions of patients reporting at least “good” control at baseline and end-of-study were as follows: Acquired PE, 1% at baseline to 32% at end-of-study (dapoxetine 30 mg); 1% to 35% (dapoxetine 60 mg), and 1% to 19% (placebo) Acquired PE, 1% at baseline to 32% at end-of-study (dapoxetine 30 mg); 1% to 35% (dapoxetine 60 mg), and 1% to 19% (placebo) Lifelong PE, 0.5% at baseline to 29% at end-of-study (dapoxetine 30 mg); 0.5% to 28% (dapoxetine 60 mg), and 0.5% to 12% (placebo)47 Lifelong PE, 0.5% at baseline to 29% at end-of-study (dapoxetine 30 mg); 0.5% to 28% (dapoxetine 60 mg), and 0.5% to 12% (placebo)47 Significant improvement in ejaculatory control with dapoxetine 30 mg or 60 mg, as compared with placebo, was found in all RCTs in Table 3.

How Sildenafil 100mg–Dapoxetine 60mg Oral Jelly Works

These improvements were noted not only at the end-of-study but at all time points in between.44,47,52 The long-term use of on-demand dapoxetine has been addressed in just one study (see Table 3), ie, a 9-month extension study of the two 12-week trials described by Pryor et al.47 All of the 1774 men enrolled in the extension study received on-demand dapoxetine 60 mg, regardless of prior treatment group in the original studies (dapoxetine 30 mg, 60 mg, or placebo). At 9 months, approximately 70% of patients reported “fair”, “good”, or “very good” control over ejaculation.53 These data represent clear evidence of a significant improvement over placebo in perceived control over ejaculation in adult patients with PE taking dapoxetine 30 mg or 60 mg on-demand. Changes from baseline in satisfaction with sexual intercourse were reported in eight studies (Table 3).

All three integrated analyses found significant improvements in viagra click and collect satisfaction with sexual intercourse at study endpoint.

Additional information

The most frequently applied instrument in studies of PE is the Premature Ejaculation Profile, which is a validated tool designed to investigate various domains in PE and assess treatment efficacy. It comprises four self-reported items, each scored on a five-point scale, ie, perceived control over ejaculation, satisfaction with sexual intercourse, personal distress related to ejaculation, and interpersonal difficulty related to ejaculation.50 In addition, the Clinical Global Impression (CGI) of change is a validated instrument often used to give a measurement of overall perceived change in PE following treatment. The CGI (also called the patient-reported global impression of change in some studies) comprises just one item, ie, “Compared to the start of the study, how would you describe your premature ejaculation now?” Patients rate their response on a seven-point scale (−3 to +3) as: much worse, worse, slightly worse, no change, slightly better, better, or much better.51 Studies reporting patient responses to items on the Premature Ejaculation Profile and the CGI of change are listed in Table 2, with quality of evidence indications. Each of the patient-reported outcomes is assessed individually below. Changes from baseline in perceived control over ejaculation are reported for eight studies (Table 3).

Pharmacokinetics and Rapid Clearance Profile

All three integrated analyses found significant improvements in control over ejaculation at study endpoint. In McMahon et al, in which the results from five RCTs were integrated, the proportion of patients who reported at least “good” control after 12 weeks of dapoxetine therapy increased from a baseline of 0.6% to 26.2% with dapoxetine 30 mg, and from 0.5% to 30.2% with dapoxetine 60 mg, compared with 0.3% to 11.2% with placebo (P < viagra online generic 0.001 for both dapoxetine doses vs placebo).45 Note: Only data for patients without erectile dysfunction are shown for consistency with other studies. Abbreviations: CGI, Clinical Global Impression; NR, not reported; RCT, randomized, placebo-controlled trial; PBO, placebo; DPX, dapoxetine. The integrated analysis by Porst et al of two studies showed no differences in control over ejaculation between those with lifelong or acquired PE (and no erectile dysfunction), suggesting that the etiology of the two forms may be similar, given that dapoxetine treatment was equally effective.47 The proportions of patients reporting at least “good” control at baseline and end-of-study were as follows: Acquired PE, 1% at baseline to 32% at end-of-study (dapoxetine 30 mg); 1% to 35% (dapoxetine 60 mg), and 1% to 19% (placebo) Acquired PE, 1% at baseline to 32% at end-of-study (dapoxetine 30 mg); 1% to 35% (dapoxetine 60 mg), and 1% to 19% (placebo) Lifelong PE, 0.5% at baseline to 29% at end-of-study (dapoxetine 30 mg); 0.5% to 28% (dapoxetine 60 mg), and 0.5% to 12% (placebo)47 Lifelong PE, 0.5% at baseline to 29% at end-of-study (dapoxetine 30 mg); 0.5% to 28% (dapoxetine 60 mg), and 0.5% to 12% (placebo)47 Significant improvement in ejaculatory control with dapoxetine 30 mg or 60 mg, as compared with placebo, was found in all RCTs in Table 3. These improvements were noted not only at the end-of-study but at all time points in between.44,47,52 The long-term use of on-demand dapoxetine has been addressed in just one study (see Table 3), ie, a 9-month extension study of the two 12-week trials described by Pryor et al.47 All of the 1774 men enrolled in the extension study received on-demand dapoxetine 60 mg, regardless of prior treatment group in the original studies (dapoxetine 30 mg, 60 mg, or placebo).

Extra Super Enjofil (Sildenafil/Dapoxetine)

At 9 months, approximately 70% of patients reported “fair”, “good”, or “very good” control over ejaculation.53 These data represent clear evidence of a significant improvement over placebo in perceived control over ejaculation in adult patients with PE taking dapoxetine 30 mg or 60 mg on-demand. Changes from baseline in satisfaction with sexual intercourse were reported in eight studies (Table 3). All three integrated analyses found significant improvements in viagra click and collect satisfaction with sexual intercourse at study endpoint. In the analysis of two 12-week studies by Pryor et al, the proportion of patients receiving dapoxetine who reported at least “fair” satisfaction increased from approximately 50% at baseline to approximately 75% (dapoxetine 30 mg) and 80% (dapoxetine 60 mg) at end-of-study, compared with approximately 55% with placebo (P < 0.001 for both dapoxetine doses vs placebo; data estimated from Pryor et al).47 Furthermore, significant differences from baseline were seen at every time point for both doses of dapoxetine vs placebo (weeks 4, 8, and 12). Importantly, the partners of subjects in these trials also reported significant improvements in satisfaction with sexual intercourse at every time point, suggesting possible associated reductions in interpersonal difficulty (not measured in these studies). In the analysis of two 12-week studies by Pryor et al, the proportion of patients receiving dapoxetine who reported at least “fair” satisfaction increased from approximately 50% at baseline to approximately 75% (dapoxetine 30 mg) and 80% (dapoxetine 60 mg) at end-of-study, compared with approximately 55% with placebo (P < 0.001 for both dapoxetine doses vs placebo; data estimated from Pryor et al).47 Furthermore, significant differences from baseline were seen at every time point for both doses of dapoxetine vs placebo (weeks 4, 8, and 12).

Prescription Required (Rx) to Buy?

This integrated analysis also found a dose-dependent effect of dapoxetine, with significantly more patients on dapoxetine 60 mg reporting at least “fair” satisfaction at every time point compared with those on dapoxetine 30 mg.47 Subanalysis of the trials published by Shabsigh et al highlighted the impact of greater perceived control over ejaculation on other aspects of sexual experience, with 74% of patients having at least a two-category increase in control-rated satisfaction with intercourse of “good” or “very good” at end-of-study.49 The integrated analysis of two studies by Porst et al showed no differences in satisfaction with intercourse between those with lifelong or acquired PE (no erectile dysfunction), indicating that the two forms potentially share some pathophysiological elements.47 The proportions of patients reporting at least “good” satisfaction with intercourse at baseline and end-of-study (pooled 12-week data from a 12-week and a 24-week study) were as follows: Acquired PE, 7% at baseline to 38% at end-of-study (dapoxetine 30 mg); 7% to 42% (dapoxetine 60 mg) and 7% to 29% (placebo) Acquired PE, 7% at baseline to 38% at end-of-study (dapoxetine 30 mg); 7% to 42% (dapoxetine 60 mg) and 7% to 29% (placebo) Life-long PE, 10% at baseline to 40% at end-of-study (dapoxetine 30 mg); 10% to 38% (dapoxetine 60 mg) and 10% to 23% (placebo) Life-long PE, 10% at baseline to 40% at end-of-study (dapoxetine 30 mg); 10% to 38% (dapoxetine 60 mg) and 10% to 23% (placebo) All three of the RCTs in Table 3 found significant improvements from baseline in satisfaction with intercourse compared with placebo at end-of-study and at all time points in between. For example, at end of the McMahon et al study, the proportions of patients who reported “good” or “very good” satisfaction with intercourse were 41.3% for dapoxetine 30 mg, 40.9% for dapoxetine 60 mg, and 29.0% for placebo (P < 0.001 for both doses of dapoxetine vs placebo).44 The effect of long-term dapoxetine treatment on satisfaction with sexual intercourse was examined in the nonrandomized extension study by Steidle et al (see Table 3).54 Irrespective of prior treatment (dapoxetine 30 mg, 60 mg, or placebo), long-term on-demand use of dapoxetine 60 mg resulted in more than 80% of patients reporting at least “fair” satisfaction with intercourse after 9 months.54 There is clear evidence from these studies that dapoxetine therapy in adult males with PE improves satisfaction with sexual intercourse in comparison with placebo. Five studies in Table 2 report changes from baseline in personal distress related to ejaculation, ie, two integrated analyses and three RCTs. Both integrated analyses found significant reductions in distress related to ejaculation at study endpoint following dapoxetine treatment. In the integrated analysis by McMahon et viagra tablet sex al, the proportions of patients who reported “quite a bit” or “extreme” personal distress decreased from 71.3% at baseline to 28.2% for dapoxetine 30 mg, and from 69.7% to 22.2% for dapoxetine 60 mg, compared with 73.5% to 41.9% with placebo (P < 0.001 for both dapoxetine doses vs placebo).45 As with the measures of ejaculatory control and sexual satisfaction, the integrated analysis of two studies by Porst et al found no differences in distress related to ejaculation between those with lifelong or acquired PE (and no erectile dysfunction).47 The proportion of patients reporting “quite a bit” or “extreme” personal distress at baseline and end-of- study were as follows: Acquired PE, 73% at baseline to 23% at end-of-study (dapoxetine 30 mg), 73% to 20% (dapoxetine 60 mg), and 73% to 41% (placebo) Acquired PE, 73% at baseline to 23% at end-of-study (dapoxetine 30 mg), 73% to 20% (dapoxetine 60 mg), and 73% to 41% (placebo) Life-long PE, 71% at baseline to 28% at end-of study (dapoxetine 30 mg), 71% to 22% (dapoxetine 60 mg), and 71% to 44% (placebo).

Tazzle 10mg (Tadalafil)

All three of the RCTs in Table 2 reporting changes in personal distress related to ejaculation found significant improvements with dapoxetine therapy from baseline compared with placebo at end-of-study. Furthermore, one of these studies also found significant differences between dapoxetine (both 30 mg and 60 mg) and placebo at all time points between baseline and end-of-study.44 In the RCT by Kaufman et al, the proportion of patients who reported being “not at all” or “a little bit” distressed by their ejaculation timing increased from approximately 5% at baseline to 54.3% at end-of-study for those who received dapoxetine 60 mg, compared with 35.3% for those who received placebo. 52 Thus, there is clear evidence that personal distress related to the timing of ejaculation is significantly reduced with dapoxetine treatment, compared with placebo, in adults with PE. Changes from baseline in interpersonal difficulty related to ejaculation following dapoxetine therapy were reported in five studies (Table 3). Two integrated analyses reporting this outcome found significant reductions in interpersonal difficulty related to ejaculation compared with placebo at study endpoint, ie, McMahon et al (integrated results from five studies) and Porst et al (integrated results from two studies).44,47 In the McMahon analysis, the proportions of patients who reported “quite a bit” or “extreme” interpersonal difficulty decreased from 36.1% at baseline to 12.3% for dapoxetine 60 mg (there is an error in the publication for the dapoxetine 30 mg results), compared with 38.5% to 23.8% with placebo (P < 0.001 for dapoxetine 60 mg vs placebo).44 The integrated analysis by Porst et al showed no differences in interpersonal difficulty related to ejaculation between those with lifelong or acquired PE (and no erectile dysfunction), adding further weight to the argument that lifelong and acquired PE have some shared etiology.47 The proportions of patients reporting “quite a bit” or “extreme” interpersonal difficulty at baseline and end-of-study were as follows: Acquired PE, 40% at baseline to 11% at the 12-week end-of-study (dapoxetine 30 mg and 60 mg) and 40% to 24% (placebo) Acquired PE, 40% at baseline to 11% at the 12-week end-of-study (dapoxetine 30 mg and 60 mg) and 40% to 24% (placebo) Lifelong PE, 34% at baseline to 14% at end-of-study (dapoxetine 30 mg), 34% to 11% (dapoxetine 60 mg), and 34% to 26% (placebo) Lifelong PE, 34% at baseline to 14% at end-of-study (dapoxetine 30 mg), 34% to 11% (dapoxetine 60 mg), and 34% to 26% (placebo) All three of the RCTs in Table 2 reporting this outcome found significant improvements from baseline in interpersonal difficulty related to ejaculation compared with placebo at the study endpoint following dapoxetine treatment.

Cite this article

Importantly, the partners of subjects in these trials also reported significant improvements in satisfaction with sexual intercourse at every time point, suggesting possible associated reductions in interpersonal difficulty (not measured in these studies). This integrated analysis also found a dose-dependent effect of dapoxetine, with significantly more patients on dapoxetine 60 mg reporting at least “fair” satisfaction at every time point compared with those on dapoxetine 30 mg.47 Subanalysis of the trials published by Shabsigh et al highlighted the impact of greater perceived control over ejaculation on other aspects of sexual experience, with 74% of patients having at least a two-category increase in control-rated satisfaction with intercourse of “good” or “very good” at end-of-study.49 The integrated analysis of two studies by Porst et al showed no differences in satisfaction with intercourse between those with lifelong or acquired PE (no erectile dysfunction), indicating that the two forms potentially share some pathophysiological elements.47 The proportions of patients reporting at least “good” satisfaction with intercourse at baseline and end-of-study (pooled 12-week data from a 12-week and a 24-week study) were as follows: Acquired PE, 7% at baseline to 38% at end-of-study (dapoxetine 30 mg); 7% to 42% (dapoxetine 60 mg) and 7% to 29% (placebo) Acquired PE, 7% at baseline to 38% at end-of-study (dapoxetine 30 mg); 7% to 42% (dapoxetine 60 mg) and 7% to 29% (placebo) Life-long PE, 10% at baseline to 40% at end-of-study (dapoxetine 30 mg); 10% to 38% (dapoxetine 60 mg) and 10% to 23% (placebo) Life-long PE, 10% at baseline to 40% at end-of-study (dapoxetine 30 mg); 10% to 38% (dapoxetine 60 mg) and 10% to 23% (placebo) All three of the RCTs in Table 3 found significant improvements from baseline in satisfaction with intercourse compared with placebo at end-of-study and at all time points in between.

• Viagra with Dapoxetine is regulated in most countries globally.
• Importing without prescription may be illegal in some regions.
• Check local laws before ordering from international sources.
• Customs may confiscate unapproved medications without warning.
• Purchase from domestic pharmacies to avoid legal issues.
• Prescription requirements protect against counterfeit or harmful drugs.
• Always keep a copy of your prescription for travel purposes.
• Report illegal sales to authorities to protect public health.
• Educate yourself on regulations to ensure compliant purchases.

For example, at end of the McMahon et al study, the proportions of patients who reported “good” or “very good” satisfaction with intercourse were 41.3% for dapoxetine 30 mg, 40.9% for dapoxetine 60 mg, and 29.0% for placebo (P < 0.001 for both doses of dapoxetine vs placebo).44 The effect of long-term dapoxetine treatment on satisfaction with sexual intercourse was examined in the nonrandomized extension study by Steidle et al (see Table 3).54 Irrespective of prior treatment (dapoxetine 30 mg, 60 mg, or placebo), long-term on-demand use of dapoxetine 60 mg resulted in more than 80% of patients reporting at least “fair” satisfaction with intercourse after 9 months.54 There is clear evidence from these studies that dapoxetine therapy in adult males with PE improves satisfaction with sexual intercourse in comparison with placebo. Five studies in Table 2 report changes from baseline in personal distress related to ejaculation, ie, two integrated analyses and three RCTs.

How does it feel in real use?

Both integrated analyses found significant reductions in distress related to ejaculation at study endpoint following dapoxetine treatment. In the integrated analysis by McMahon et viagra tablet sex al, the proportions of patients who reported “quite a bit” or “extreme” personal distress decreased from 71.3% at baseline to 28.2% for dapoxetine 30 mg, and from 69.7% to 22.2% for dapoxetine 60 mg, compared with 73.5% to 41.9% with placebo (P < 0.001 for both dapoxetine doses vs placebo).45 As with the measures of ejaculatory control and sexual satisfaction, the integrated analysis of two studies by Porst et al found no differences in distress related to ejaculation between those with lifelong or acquired PE (and no erectile dysfunction).47 The proportion of patients reporting “quite a bit” or “extreme” personal distress at baseline and end-of- study were as follows: Acquired PE, 73% at baseline to 23% at end-of-study (dapoxetine 30 mg), 73% to 20% (dapoxetine 60 mg), and 73% to 41% (placebo) Acquired PE, 73% at baseline to 23% at end-of-study (dapoxetine 30 mg), 73% to 20% (dapoxetine 60 mg), and 73% to 41% (placebo) Life-long PE, 71% at baseline to 28% at end-of study (dapoxetine 30 mg), 71% to 22% (dapoxetine 60 mg), and 71% to 44% (placebo). All three of the RCTs in Table 2 reporting changes in personal distress related to ejaculation found significant improvements with dapoxetine therapy from baseline compared with placebo at end-of-study. Furthermore, one of these studies also found significant differences between dapoxetine (both 30 mg and 60 mg) and placebo at all time points between baseline and end-of-study.44 In the RCT by Kaufman et al, the proportion of patients who reported being “not at all” or “a little bit” distressed by their ejaculation timing increased from approximately 5% at baseline to 54.3% at end-of-study for those who received dapoxetine 60 mg, compared with 35.3% for those who received placebo.

52 Thus, there is clear evidence that personal distress related to the timing of ejaculation is significantly reduced with dapoxetine treatment, compared with placebo, in adults with PE.

• Viagra with Dapoxetine is not recommended for women or children.
• Men with severe kidney or liver issues should avoid this drug.
• Those with retinitis pigmentosa may face increased vision risks.
• Heart patients must get clearance before starting treatment.
• Diabetic men may require lower doses due to health complications.
• High blood pressure patients should monitor cardiovascular response.
• Consult specialist if you have a history of stroke or seizures.
• Prostate surgery patients may have altered drug sensitivity.
• Age over 65 may require reduced dosage for safety reasons.

Changes from baseline in interpersonal difficulty related to ejaculation following dapoxetine therapy were reported in five studies (Table 3). Two integrated analyses reporting this outcome found significant reductions in interpersonal difficulty related to ejaculation compared with placebo at study endpoint, ie, McMahon et al (integrated results from five studies) and Porst et al (integrated results from two studies).44,47 In the McMahon analysis, the proportions of patients who reported “quite a bit” or “extreme” interpersonal difficulty decreased from 36.1% at baseline to 12.3% for dapoxetine 60 mg (there is an error in the publication for the dapoxetine 30 mg results), compared with 38.5% to 23.8% with placebo (P < 0.001 for dapoxetine 60 mg vs placebo).44 The integrated analysis by Porst et al showed no differences in interpersonal difficulty related to ejaculation between those with lifelong or acquired PE (and no erectile dysfunction), adding further weight to the argument that lifelong and acquired PE have some shared etiology.47 The proportions of patients reporting “quite a bit” or “extreme” interpersonal difficulty at baseline and end-of-study were as follows: Acquired PE, 40% at baseline to 11% at the 12-week end-of-study (dapoxetine 30 mg and 60 mg) and 40% to 24% (placebo) Acquired PE, 40% at baseline to 11% at the 12-week end-of-study (dapoxetine 30 mg and 60 mg) and 40% to 24% (placebo) Lifelong PE, 34% at baseline to 14% at end-of-study (dapoxetine 30 mg), 34% to 11% (dapoxetine 60 mg), and 34% to 26% (placebo) Lifelong PE, 34% at baseline to 14% at end-of-study (dapoxetine 30 mg), 34% to 11% (dapoxetine 60 mg), and 34% to 26% (placebo) All three of the RCTs in Table 2 reporting this outcome found significant improvements from baseline in interpersonal difficulty related to ejaculation compared with placebo at the study endpoint following dapoxetine treatment.